HIV vaccine development and clinical trials

Area of Science:

• Biomedical research
• Vaccinology
• Infectious diseases

Background:

• The global human immunodeficiency virus (HIV) pandemic necessitates urgent vaccine development.
• Designing vaccines for chronic viral infections like HIV presents significant biological challenges.
• First-generation prophylactic HIV vaccine candidates have demonstrated safety and immunogenicity in Phase I trials.

Purpose of the Study:

• To summarize the progress in the development of HIV vaccines.
• To discuss the ongoing evaluation of HIV vaccine candidates in human trials.
• To explore potential strategies for optimizing HIV vaccine efficacy trials.

Main Methods:

• Review of completed Phase I human trials for prophylactic HIV vaccine candidates.
• Description of ongoing Phase II trials for HIV subunit envelope vaccines.
• Outline of preparations for Phase III efficacy trials.
• Summary of preliminary studies on active and passive immunization for preventing vertical HIV transmission.

Main Results:

• Over a dozen first-generation prophylactic HIV vaccine candidates have successfully completed Phase I trials.
• Phase I trials confirmed the safety and immunogenicity of these HIV vaccine products in adults.
• A Phase II trial involving two HIV subunit envelope vaccines in high-risk adults is currently underway.
• Preparations for Phase III efficacy trials are in progress.

Conclusions:

• Encouraging progress has been made in HIV vaccine development despite formidable biological hurdles.
• Ongoing trials are evaluating HIV vaccine candidates in adults at high risk of infection.
• Evaluating HIV vaccine efficacy in HIV-infected pregnant women and their offspring may be more efficient than in sexually exposed adults.